How does systematic profiling with NGS optimize genomic and molecular stratification for prostate cancer, and what actionable subgroups and aberrations have you identified?

How does systematic profiling with NGS optimize genomic and molecular stratification for prostate cancer, and what actionable subgroups and aberrations have you identified?

In what way does systematic profiling with NGS optimize genomic and molecular stratification for prostate cancer, and what actionable subgroups and aberrations have you identified based on comprehensive genomic assessment?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Prof. Johann De Bono, MD, PhD

Prof. Johann De Bono, MD, PhD

Professor of Experimental Cancer Medicine
Honorary Consultant Medical Oncologist
Royal Marsden Hospital
Head of the Division of Clinical Studies
Institute of Cancer Research
London, UK